Information for Outsourcing Facilities

Sign up for email alerts on Compounding

The Drug Quality and Security Act, signed into law on November 27, 2013, created a new section 503B in the Federal Food, Drug, and Cosmetic Act. Under section 503B, a compounder can become an outsourcing facility.

The law defines an outsourcing facility as a facility at one geographic location or address that is engaged in the compounding of sterile drugs; has elected to register as an outsourcing facility; and complies with all of the requirements of section 503B.

Drugs compounded by an outsourcing facility can qualify for exemptions from FDA approval requirements and the requirement to label products with adequate directions for use, but not from current good manufacturing practice (CGMP) requirements.

Outsourcing facilities:

  • must comply with CGMP requirements;
  • are inspected by FDA according to a risk-based schedule; and
  • must meet certain other conditions, such as reporting adverse events and providing FDA with certain information about the products they compound.

General information for Outsourcing Facilities, and Entities Considering Whether to Register as an Outsourcing Facility

Product Reporting Information

Section 503B(b) of the FD&C Act requires outsourcing facilities to report to FDA, upon initial registration and each June and December, the drug products that they compounded during the previous six-month period. As FDA described in guidance, the agency is posting this information to assist the public in identifying outsourcing facilities that have produced certain drug products that they need.

This outsourcing facility product report (XLS - 252 KB, updated 4/20/2018) lists drug products that outsourcing facilities reported were produced during prior reporting periods, beginning with the December 2016 to May 2017 period. This retrospective report does not identify drug products that outsourcing facilities intend to produce in the future. Additionally, this report does not contain an exhaustive list of the drug products that all outsourcing facilities have produced since not all outsourcing facilities have submitted drug product reports to the agency in compliance with the law and some outsourcing facilities did not compound any drug products during the reporting period.  

Policy Documents Applicable to Outsourcing Facilities



Page Last Updated: 06/22/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English